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• This is the ﬁrst randomized controlled trial on the effects of Anma therapy (Japanese massage).
• Anma therapy reduced subjective physical complaints in gynecologic cancer survivors.
• It is possible that Anma therapy inhibits the sympathetic nervous system.☆ Trial registration: This trial was registered with the U
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Available online 16 July 2016Objectives. Cancer survivors often have physical and psychological complaints after standard cancer treat-
ment. We conducted a randomized control trial to evaluate the physical and psychological/emotional effects of
Anma therapy (Japanese massage, AMT) in gynecologic cancer survivors. The primary objective was to verify
the effects of 8 consecutive weeks of weekly AMT. The secondary objective was to conﬁrm the immediate effects
of single-session AMT. We report here results of the physical effects of AMT.
Methods. Forty participants were randomly allocated to an AMT group that received one 40-min AMT session
per week for 8 weeks and a no-AMT group. The primary endpoint was severity of subjective physical complaints
assessed using a visual analogue scale (VAS). Secondary endpointswere urine and saliva analyses and psycholog-
ical/emotional questionnaire scores.
Results. In the primary analysis, least-squares means (LSM) estimates of VAS score improvement over the
8 weeks were−21.5 (95% conﬁdence interval [CI],−30.1 to−12.8, P = 0.0017) in the AMT group (n = 20)
and 0.8 (95%CI,−7.7 to 9.2, P = 0.89) in the no-AMT group (n = 20). The difference in the LSM estimates be-
tween the groups was−22.2 (95%CI,−34.4 to−10.1, P = 0.0007). There were signiﬁcant differences in VAS
score and urinary epinephrine between before and after the intervention session, demonstrating the superiority
of AMT.
Conclusions.A single AMT session reduces the severity of subjective physical complaints andmight inhibit the
sympathetic nervous system in gynecologic cancer survivors. Receiving weekly AMT sessions for eight weeks ef-
fectively continues to reduce the severity of subjective physical complaints.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Cancer has been the leading cause of death in the Japanese popula-
tion since 1981. Average yearly estimates for the period 2025–2029
put the number of cancer deaths at 230,000 men and 160,000 women
and cancer incidence at 530,000 men and 390,000 women in Japan
[1]. Both these estimates are expected to slow after 2015 for men; how-
ever, they are expected to continue increasing at the present rate for
women, especially with regard to incidence of cancers in the oral cavity
and pharynx, kidney and urinary tract, uterus, lung, pancreas, and cervixthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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have improved the prognosis of cancer patients and increased the num-
ber of cancer survivors in Japan [2], interest has been shifting from rad-
ical treatment options toward ensuring a better quality of life (QOL) to
cope with the disease [3].
Massage therapy is one of themost commonly used complementary
and alternative medicines for cancer patients and survivors to manage
physical, emotional, and psychological complaints. In relation to gyne-
cologic cancers, Mirabeau-Beale et al. revealed that massage is one of
the most commonly used modalities by ovarian cancer survivors pri-
marily to improve QOL [4]. Also, according to Matulonis et al., of the
22.4% of ovarian cancer survivors who used massage to treat their can-
cer, 100% used it to improve QOL, 61.5% used it to improve side effects,
and 15.4% used it for movement and physical therapy [5]. Actually, 20%
of ovarian cancer survivors have reported long-term side effects of
treatment, including problems related to abdominal and gynecologic
symptoms and neurotoxicity [6]. Ovarian cancer survivors have also re-
ported signiﬁcant concerns related to pain and other complaints [7].
One of the most common and popular forms of complementary and
alternative medicine in Japan is Japanese massage therapy, or Anma
massage therapy (AMT). It has long been used by healthy persons, the
elderly, disease-free survivors, patients with disease, and cancer survi-
vors to promote health, manage and cure various complaints, and pre-
vent disease. However, because the effectiveness of AMT has not been
established for cancer survivors and patients, they must determine for
themselves, based solely on anecdotal information, whether or not to
receive AMT. To address this situation, scientiﬁc studies on AMT are
needed.
After conducting a preliminary study for cancer survivors who
had undergone surgery for uterine cervical or endometrial cancer
(FIGO stage Ia1 – Iia) and verifying the effects of AMT [8], based on
our preliminary ﬁndings we designed and conducted the present
randomized controlled trial. The design has been published previ-
ously [9]. The primary objective of this trial was to verify physical
and psychological/emotional effects of 8 consecutive weeks of week-
ly AMT in gynecologic cancer survivors. The secondary objective was
to conﬁrm the physical and psychological/emotional immediate ef-
fects of single AMT intervention session.
Our hypotheses were that AMT for gynecologic cancer survivors
would: (H1) improve more subjective physical complaints appearing
after standard cancer treatment than in controls immediately after a
single intervention session, and these effects would be sustained by 8
consecutive weeks of once-weekly AMT sessions; (H2) enhance psy-
chological andmood statesmore so than in the controls; (H3) potential-
ly improve coping styles in cancer survivors through the relationship
with a massage therapist; and (H4) change the values of some kinds
of biochemical markers related to stress release, the autonomic nervous
system, or the immune system.
2. Methods
This trial was approved by theMedical Ethics Committee of Tsukuba
University of Technology, Japan, where the study setting and coordinat-
ing ofﬁce were located, on September 27, 2012 (Approval No. 5).
Trial gynecologists whoworked at another hospital recruited partic-
ipants whomet the eligibility criteria, and they conﬁrmed at every clin-
ical session that participants did not fall into the exclusion criteria. Trial
inclusion criteriawere: (a) histologically conﬁrmed uterine cervical, en-
dometrial, ovarian, fallopian tubal, or peritoneal cancer in the past;
(b) no recurrence of such cancer for ≥3 years since ﬁnishing standard
medical treatment; (c) ≥20 years of age at the date of registration to
the trial; and (d) eligibility for the trial conﬁrmed by gynecologists re-
sponsible for the patient. Trial exclusion criteria were: (a) current active
infection(s); (b) serious concurrent disease of the heart, liver, or kidney;
and (c) severe mental disorder(s). Next, the gynecologists sent intro-
duction forms by facsimile to the coordinating ofﬁce. After receipt, thecoordinating ofﬁce scheduled a meeting date with each cancer survivor
to provide themwith trial information (oral and written) at the coordi-
nating ofﬁce. Patients subsequently submitted a consent form to partic-
ipate in the trial by hand or via facsimile.
After ﬁnishing enrolment, randomization was performed. The trial
statistician generated the allocation sequence by block randomization.
However, allocation adjustment factors were not set in the trial due to
currently insufﬁcient evidence on factors inﬂuencing the effectiveness
of AMT. Before the trial began, the trial statistician created a table of ran-
domized assignment for management by 2 employees at the coordinat-
ing ofﬁce.
2.1. AMT group
This group received treatment byAMT. Protocol treatmentwas com-
pleted once the participant ﬁnished receiving the eighth and ﬁnal 40-
min AMT session. Sessions were given once a week during the consecu-
tive 8-week intervention period. Following the AMT protocol, partici-
pants were given a full body AMT session that excluded the face, head,
and abdomen while lying on a massage table. We conducted assess-
ments before the ﬁrst AMT session (pre-session, baseline), after the
ﬁrst AMT session (post-session), and before the last (8th) AMT session
(8-week follow-up).
2.1.1. AMT protocol
First, the massage therapist interviewed the participant about sub-
jective physical complaints appearing after standard cancer treatment
and thenmanually checked the affected area(s) formuscle tension, stiff-
ness, induration, tenderness, knocking pain, malalignment of the spine,
edema, and area of pain/discomfort/palsy, and other such conditions.
Second, while the participant lay on the right side of the body on amas-
sage table, the left side of the body was massaged. The massage started
at the upper shoulder and then moved to the back, lower back, upper
limb (shoulder joint to wrist joint), hand (carpus to ﬁnger tips), and
neck (superior nuchal line along the neck to the side of the 7th cervical
vertebra). The massage then returned to the trunk (shoulder to lower
back) following these areas: buttock, lower limb (gluteal fold to ankle
joint), and foot (heel to toes). Third, while the participant was lying
on the left side, the opposite side of the body was massaged in the
same order. Finally, while the participant was lying in a prone position,
the massage was repeated brieﬂy on the shoulders, back, lower back,
lower limbs, and feet simultaneously on both sides. During themassage,
the therapist focused the massage on speciﬁc locations related to the
participant's physical complaints. This massage procedure was the
same as that used in our previous studies [8,10], using massage tech-
niques considered standard versions of common AMT and as described
in detail by Kimura [11]. AMT mostly targets the muscles by kneading
(thumb, 2-ﬁnger [thumb and foreﬁnger], 4-ﬁnger, carpus, palm, and
palm grasp), which is the most commonly used technique. Thumb
kneading is most frequently used, followed by pressing (thumb, carpus,
and palm), and then with lesser amounts of stroking (2 hands, thumb,
and ﬁngertips). AMT is performed through the clothing, with stimula-
tion intensity applied according to each patient's range of comfort. A
therapist with a national massage practitioner license from Japan and
N20 years of experience performed all massage sessions to avoid differ-
ences in technical capabilities.
2.2. No-AMT group
The control group was followed as usual by their medical doctors
and did not receive AMT treatment. They met with the massage thera-
pist at the coordinating ofﬁce on the ﬁrst day of their scheduled trial pe-
riod to receive a 40-min semi-structured chat intervention with no
massage while seated. Assessments were conducted before the inter-
vention session (pre-session, baseline) and after the intervention ses-
sion (post-session). Participants returned to the ofﬁce on the last day
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after which they received a single 40-min AMT session as a gift for par-
ticipating in the study.
2.2.1. Chat protocol and chat policy
The semi-structured chat protocol was designed to facilitate natural
and relaxed conversation that was positive and honest. First, aswith the
AMT group, themassage therapist conducted an interview and checked
by hand the participant's physical condition after standard cancer treat-
ment. Second, to enhance self-disclosure or willingness to reveal per-
sonal information to others, the therapist interviewed the participant
stating, “You've had a huge experience, getting a diagnosis of cancer
and then making it through cancer safely. Could you tell me what you
felt, what you thought, what you did at the time, and anything else
you would like to add?” All participants had much to say about their
memories and thoughts. Next, to facilitate positive thinking, the thera-
pist asked, “Have you had any happy or pleasant things happen to you
recently, and could you tell me about them?” The therapist paid full at-
tention and repeated the participant's words with the same emotional
expression. At the end of the session, using a positive feedback method,
the therapist repeated what she felt were themost emotionally impact-
ful words spoken by the patient, shared her feelings about the
participant's words, and then empathized with the participant.
2.3. Outcomes
2.3.1. Primary outcome measure
The primary outcomemeasure was the change in severity of subjec-
tive physical complaints appearing after standard cancer treatment, de-
termined using a visual analogue scale (VAS). The VAS was a sheet of
paper with a 100-mm line from left (no physical complaint) to right
(worst imaginable physical complaint). Participants were asked to indi-
cate the severity of their physical complaint at the time by placing a tick
on the line, and length from the left side to the tick was measured and
used as theVAS score. Scores ranged from0 to 100,with higher score in-
dicating more severe degree of physical complaint.
2.3.2. Secondary outcome measures
Secondary outcome measures included biochemical measures and
self-administered questionnaires.
2.3.2.1. Biochemical measures. Urine samples were provided to assay
concentrations of epinephrine, norepinephrine, dopamine, and 8-
hydroxydeoxyguanosine (8-OHdG). Saliva samples were also taken to
assay concentrations of chromogranin A (CgA), cortisol, and secretory
immunoglobulin A (s-IgA). Salivette® (Sarstedt, Aktiengesellschatt &
Co., Germany), was used to take 2-mL saliva samples. Brieﬂy, a swab
was removed from the Salivette, chewed 120 times gently for two mi-
nutes in synch with a metronome, then returned to the device.
2.3.2.2. Self-administered questionnaires. To clarify the effects on psycho-
logical/mood status, coping style with cancer, and QOL, we used the fol-
lowing instruments.
(1) Hospital Anxiety Depression Scale, Japanese Version (HADS)
(2) Proﬁle of Mood States - Brief Japanese Version (POMS)
(3) Measure of Adjustment to Cancer, Japanese version (MAC)
(4) Japanese version of the European Organization for Research and
Treatment of Cancer QLQ-C30 version 3.0 (EORTC QLQ-C30)
2.4. Data collection
The HADS, MAC, and EORTC QLQ-C30 were administered pre-
session and at the 8-week follow-up. The VAS and POMSwere adminis-
tered pre-session, post-session, and at the 8-week follow-up. Urine andsaliva samples were also taken pre-session, post-session, and at the 8-
week follow-up. Immediately after ﬁnishing interventions, urine and
saliva samples were frozen and taken to a clinical laboratory testing
company the next morning (SRL Inc., Tsukuba branch, Tsuchiura,
Japan) for assaying. To avoid alteration of quantities of biochemical ma-
terials by the circadian rhythm, all measurement sessions began at
14:30. Fig. 1 shows the timing of sample and questionnaire collection
in detail.
2.5. Statistical methods
Based on our preliminary data [8], we assumed that themean differ-
ence would be−20.8 in the AMT group, unchanged (e.g., 0) in the no-
AMT group, and that the standard deviation would be 19.6 in both
groups. To test these differences between the two groups using a 5%
Type I error rate and 90% power, we needed a sample size of 14 partic-
ipants per group. Based on sensitivity analyses for sample size calcula-
tion, the planned sample size was determined to be 30 participants
per group [9]. Although the present sample size did not reach the
planned sample size, sufﬁcient power for primary analysis was
acquired.
We performed all efﬁcacy analysis according to the modiﬁed
intention-to-treat principle, which included all participants who re-
ceived at least one AMT session in the AMT group and one chat session
in the no-AMT group. Additionally, we performed as-treated analyses,
inwhichparticipantswere classiﬁed according to the treatment actually
received (not shown).
The primary endpoint was VAS score improvement over the 8-week
trial period. For primary analysis, we used the analysis of covariance to
comparemean changes in VAS score over the 8weeks between theAMT
group and the no-AMT group, adjusting for baseline VAS score and age.
We used a two sample t-test with Satterthwaite's approximation to
compare mean changes and the paired t-test to evaluate mean changes
in VAS score for each group. For thesemeanVAS score changes and their
differences, we also calculated two-sided 95% conﬁdence intervals (CIs)
to evaluate clinical effects.
For the secondary endpoints, we did not considermultiplicity issues.
In all analyses, categorical variables are described in terms of frequency
and percentage. The distributions of continuous variables are described
usingmeans, standard deviations (SDs), medians, quartiles, and ranges.
The Wilcoxon signed-rank test or the Mann-Whitney U test was used
for non-normally distributed data. Pearson's chi-square test was used
to test differences in categorical variables. All reported P-values are
two-sided, and all signiﬁcance levelswere set at 0.05. SAS 9.3 (SAS Insti-
tute, Cary, NC, USA) was used for all analyses.
3. Results
The start date for recruitment was October 13, 2012. The ﬁrst
participant's trial began on November 2, 2012 and the 8-week follow-
up of the 40th participant concluded on November 1, 2014. In this arti-
cle, we present the results for the physical effects of AMT as change in
VAS score as the primary endpoint and change in biomarker levels to
verify (H1) and (H4). The results for the psychological/emotional ef-
fects, discussed in relation to (H2) and (H3), will be reported separately.
3.1. Baseline characteristics
Fifty-eight participants were eligible for the study and 40 partici-
pants submitted the consent form and were enrolled (Fig. 2). Twenty
participants were randomized to the AMT group and 20 to the no-
AMT group (median age, 53.0 and 55.5 years; median age at cancer
onset, 42.5 and 43.5 years; median duration from onset, 8.3 and
8.6 years, respectively) (Table 1). One participant was randomized to
the no-AMT group but actually received AMT intervention. Thus, 21
Fig. 1. Intervention and measurement procedure.
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ipants completed their interventions.
Twenty-ﬁve (62.5%) participants had uterine cervical cancer, 10
(25.0%) had endometrial cancer, and 5 (12.5%) had ovarian cancer. Sev-
enty percent of participants had stage I cancer. Surgery was undertaken
in 37 (92.5%) participants and lymph node dissection in 30 (75.0%).
Eleven participants (27.5%) had received chemotherapy and 13
(32.5%) had received radiation therapy. Sociodemographic and clinical
variables revealed no signiﬁcant differences between the AMT and no-
AMT groups (Table 1).3.2. VAS score
In the primary analysis, least-squares mean (LSM) estimates of VAS
score improvement over the 8-week trial period were−21.5 (95%CI,
−30.1 to−12.8, P = 0.0017) in the AMT group and 0.8 (95%CI,−7.7
to 9.2, P = 0.89) in the no-AMT group. The difference in the LSMs be-
tween the two groups was −22.2 (95%CI, −34.4 to −10.1, P =
0.0007), demonstrating the superiority of AMT. A statistical difference
in the LSMs was also observed in the supportive as-treated analysis
(LSM [95%CI], 23.3 [−35.2 to−11.4], P = 0.0003). Mean improvement
Fig. 2. CONSORT ﬂowchart of participant recruitment.
Table 1
Demographic and clinical characteristics of cancer survivors.
Characteristic AMT No AMT P
value
(n = 20) (n = 20)
Age, median (min-max) 53.0 (40–69) 55.5 (41–75) 0.60†
Age at cancer onset, years, median
(min-max)
42.5 (33–59) 43.5 (26–70) 0.68†
Duration from cancer onset, years,
median (min-max)
8.3 (3.1–21.3) 8.6 (3.2–27.8) 0.80†
Site of gynecologic cancer
Uterine cervix 11 (55%) 14 (70%) 0.34††
Endometrium 7 (35%) 3 (15%)
Ovary 2 (10%) 3 (15%)
FIGO stage
I 13 (65%) 15 (75%) 0.73††
II–IV 7 (35%) 5 (25%)
Surgery
Yes 20 (100%) 17 (85%) 0.23††
No 0 (0%) 3 (15%)
Lymph node dissection
Yes 16 (80%) 14 (70%) 0.72††
No 4 (20%) 6 (30%)
Chemotherapy
Yes 6 (30%) 5 (25%) 1.00††
No 14 (70%) 15 (75%)
Radiotherapy
Yes 8 (40%) 5 (25%) 0.50††
No 12 (60%) 15 (75%)
AMT: Anma therapy.
† P value calculated using the Mann-Whitney U test.
†† P value calculated using Pearson's chi-square test.
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−41.1 to −22.4, P b 0.0001) in the AMT group and −7.2 (95%CI,
−11.9 to −2.5, P = 0.0045) in the no-AMT group. The difference in
the means between the two groups was −24.6 (95%CI, −34.7 to
−14.3, P b 0.0001), indicating the immediate efﬁcacy of AMT (Table 2).
3.3. Biomarkers
Between the two groups, a signiﬁcant difference was found during
the 8-week trial period in salivary CgA (median difference, 0.6 in AMT
and−1.2 in no-AMT, P = 0.025). Moreover, signiﬁcant differences in
pre- and post-session levelswere found in urinary epinephrine (median
difference,−1.5 in AMT and 5.1 in no-AMT, P = 0.0011), norepineph-
rine (median difference,−21 in AMT and 37 in no-AMT, P = 0.0048),
and dopamine (median difference,−131 in AMT and 168 in no-AMT,
P=0.010). In the AMT group, a signiﬁcant decreasewas found between
the pre- and post-session levels of epinephrine (P= 0.0018). In the no-
AMT group, signiﬁcant increases were seen in epinephrine (P= 0.014),
norepinephrine (P = 0.033), and dopamine (P = 0.030) and a signiﬁ-
cant decrease was seen in CgA (P = 0.0046) (Table 2).
4. Discussion
The results of the primary outcome, namely signiﬁcant changes in
VAS score, indicate the severity of subjective physical complaints
appearing after standard cancer treatment. Therefore, hypothesis (H1)
was veriﬁed. In a review of the physiological and therapeutic effects of
massage, Goats found that effects of forceful massage on increased
local blood ﬂow were longer lasting than those of gentle pressure and
represented a potent means to accelerate healing, and that massage
Table 2
Changes in physical outcomes (modiﬁed intention-to-treat population).
Visual analogue scale (VAS) AMT No AMT P value
N Mean (SD) N Mean (SD)
Pre-session 20 50 ± 23 20 50 ± 19 −24.6 (−34.7 to−14.3) b0.0001⁎⁎⁎††
Post-session 20 18 ± 16 20 43 ± 22
Change from pre-session mean (95%CI) 20 −31.8 (−41.1 to−22.4) 20 −7.2 (−11.9 to−2.5)
P value† b0.0001⁎⁎⁎ 0.0045⁎⁎
8-week follow-up 20 30 ± 25 20 51 ± 20 −22.2 (−34.4 to−10.1) 0.0007⁎⁎⁎§
8-week change LSM (95%CI)§ 20 −21.5 (−30.1 to−12.8) 20 0.8 (−7.7 to 9.2)
P value† 0.0017⁎⁎ 0.8860
Biomarkers AMT No AMT P value††
N Median (quartiles) N Median (quartiles)
Urinary epinephrine μg/L
Pre-session 20 11.5 (6.5 to 23.7) 20 7.0 (4.9 to 12.9) 0.0011⁎⁎
Post-session 20 7.4 (3.5 to 18.9) 20 11.4 (7.8 to 15.6)
Change from pre-session 20 −1.5 (−5.4 to−0.2) 20 5.1 (0.3 to 9.0)
P value† 0.0018⁎⁎ 0.0140⁎
8-week follow-up 20 9.4 (4.6 to 12.9) 20 6.4 (4.7 to 12.7)
8-week change 20 −0.9 (−8.2 to 1.3) 20 −0.5 (−4.7 to 3.8) 0.3993
P value† 0.2731 0.8052
Urinary norepinephrine μg/L
Pre-session 20 125 (50 to 193) 20 100 (37 to 137) 0.0048⁎⁎
Post-session 20 81 (55 to 161) 20 113 (74 to 150)
Change from pre-session 20 −21 (−43 to 16) 20 37 (18 to 62)
P value† 0.0973 0.0328⁎
8-week follow-up 20 116 (60 to 151) 20 97 (44 to 148)
8-week change 20 −15 (−86 to 67) 20 5 (−45 to 41) 0.5642
P value† 0.3683 0.7841
Urinary dopamine μg/L
Pre-session 20 759 (358 to 1158) 20 503 (204 to 1215) 0.0104⁎
Post-session 20 596 (425 to 803) 20 635 (445 to 1337)
Change from pre-session 20 −131 (−452 to 156) 20 168 (62 to 362)
P value† 0.0826 0.0296⁎
8-week follow-up 20 637 (394 to 1500) 20 649 (360 to 1034)
8-week change 20 −201 (−687 to 369) 20 106 (−179 to 287) 0.3847
P value† 0.3884 0.4304
Urinary 8-hydroxydeoxyguanosine (8-OHdG) ng/mL
Pre-session 20 10.6 (9.3 to 14.4) 14 11.4 (9.4 to 13.7) 0.2113
Post-session 19 10.4 (9.0 to 15.6) 20 10.6 (9.7 to 12.7)
Change from pre-session 19 0.3 (−1.5 to 1.9) 14 −0.6 (−1.5 to 0.5)
P value† 0.5871 0.0991
8-week follow-up 18 11.8 (9.7 to 14.4) 17 11.3 (9.1 to 13.0)
8-week change 18 1.0 (−1.6 to 2.5) 14 −1.1 (−4.8 to 3.1) 0.4420
P value† 0.3987 0.8672
Salivary chromogranin A (CgA) pmoL/mg protein
Pre-session 20 3.3 (2.1 to 5.5) 17 3.8 (2.5 to 5.5) 0.0965
Post-session 20 2.7 (2.2 to 4.3) 19 2.9 (1.5 to 6.7)
Change from pre-session 20 −0.4 (−1.2 to 0.8) 17 −1.2 (−1.7 to−0.6)
P value† 0.5039 0.0046⁎⁎
8-week follow-up 20 3.3 (1.8 to 8.2) 19 3.3 (1.4 to 4.2)
8-week change 20 0.6 (−1.3 to 1.8) 17 −1.2 (−2.7 to 0.0) 0.0254⁎
P value† 0.4980 0.0067⁎⁎
Salivary cortisol μg/dL
Pre-session 20 0.07 (0.06 to 0.08) 18 0.08 (0.06 to 0.15) 0.4030
Post-session 20 0.06 (0.06 to 0.07) 19 0.08 (0.06 to 0.12)
Change from pre-session 20 −0.01 (−0.02 to 0.00) 18 0.00 (−0.02 to 0.00)
P value† 0.0801 0.2686
8-week follow-up 20 0.09 (0.06 to 0.13) 19 0.07 (0.06 to 0.12)
8-week change 20 0.00 (−0.01 to 0.03) 18 −0.02 (−0.06 to 0.00) 0.1605
P value† 0.4716 0.4257
Secretory immunoglobulin A (s-IgA) μg/mL
Pre-session 20 281 (170 to 433) 19 299 (205 to 415) 0.9889
Post-session 20 276 (168 to 407) 19 287 (176 to 458)
Change from pre-session 20 −7 (−123 to 108) 19 −8 (−133 to 70)
P value† 0.9854 1.0000
8-week follow-up 20 177 (135 to 281) 19 259 (152 to 356)
8-week change 20 −56 (−219 to 99) 19 −51 (−212 to 64) 0.7696
P value† 0.5459 0.1819
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associated muscle spasms, and permit improved function [12]. Also,
connective tissue manipulation that manually stimulates skin over the
thoracic and lumbar spine triggers cutaneovisceral reﬂexes that cause
vasodilation [12]. The same mechanisms observed in Western massage
techniques are thought to operate in AMT. Moreover, by kneading and
pressing muscles, muscle spindles are pulled and extended, and that
stimulation causes various reﬂexes, including the stretch reﬂex and an-
tagonistic inhibition, as well as somatic sensory impulses to travel up to
the brain to coordinate muscle function through the neural circuit net-
work. On the way, these afferent neurons undergo changes in the me-
dulla and thalamus, possibly affecting the autonomic nervous system
and endocrine/hormonal systems. We suggest that these mechanisms
function in AMT to improve various subjective physical complaints in
cancer survivors.
According to a literature review byMoraska et al. [13], seven studies
have reported data on urinary catecholamines following massage ther-
apy. Five of those studies reported no signiﬁcant change in epinephrine
or norepinephrine over the study duration [14–18]. These results are in
line with those of the present study.
Additionally, the present study revealed a signiﬁcant reduction in
epinephrine, but no changes in norepinephrine and dopamine immedi-
ately after an AMT session; in contrast, immediately after the chat ses-
sion, there was a signiﬁcant increase in norepinephrine and
dopamine. Norepinephrine, indeed, may be known as a stress marker;
however, it has been reported that norepinephrine may contribute to
cognitive function [19,20]. Serotonin & norepinephrine reuptake inhib-
itors have recently been used to increase serotonin, norepinephrine,
and dopamine to treatmood disorders such as depression. These differ-
ences between the two groups were signiﬁcant and suggest that the
sympathetic nervous systemmight be inhibited by AMT andmental ac-
tivity might be activated [21] by the chat session.
Studies have recently used salivary CgA concentration as a new
stress index to reﬂect the sympathetic nervous system [22,23]. In the
present study, both groups showed CgA concentration had decreased
post-session compared with pre-session values; however, only the no-
AMT group showed a signiﬁcant reduction, with no signiﬁcant differ-
ence between the two groups. However, at 8 weeks, the reduction
remained signiﬁcant in the no-AMT group, with a signiﬁcant difference
between the two groups. These results suggest that the sympathetic
nervous systemmight also be inhibited in the no-AMT group. According
toO'Connor et al. [24], salivary CgAmight have theproperty of not being
easily affected by physical stress, which is different from other
sympathoneural biomarkers. Thus, Miki suggests that the secretory
mechanism of salivary CgA might differ from that of urinary norepi-
nephrine excretion [25]. Based on the present results, epinephrine out-
put might be primarily inﬂuenced by physical activity through AMT,
whereas CgA might be more responsive to mental activity by the chat
intervention. This chat intervention might have dimensions of psycho-
therapy due to its inclusion of self-disclosure [26,27], positive thinking
[28–30], and a positive feedback method. It might possibly act directly
on the brain to inhibit sympathetic nervous system activity and sustain
the effect longer than physical stimulation.
No signiﬁcant differences were observed in urinary 8-OHdG (as an
oxidative stressmarker), salivary cortisol (which becomes synonymousNotes to Table 2:
AMT: Anma therapy; CI: conﬁdence interval; LSM: least-squares mean; VAS: visual analogue s
VAS:
Biomarkers:
* P b 0.05.
** P b 0.01.
*** P b 0.001.
† P value calculated using paired t-test.
†† P value calculated using a two-sample t-test.
§ LSM and P value calculated using analysis of covariance.
† P value calculated using Wilcoxon's signed-rank test.
†† P value calculated using the Mann-Whitney U test.with stress hormone), or s-IgA (which is thought to reﬂect immune
activity).
This was a pilot RCT study on the use of individualized AMT for gyne-
cologic cancer survivors. This study has some limitations. First, the study
was conducted in a small city (population 200,000), so the sample size
was small. Furthermore, eligibility criteria were very open. Thus, it is dif-
ﬁcult to generalize the results from this RCT to the wider effectiveness of
AMT for cancer survivors. A subsequent multicenter RCT should be used
to verify our ﬁndings and recruit a more consistent population, as well
as limit the characteristic of the sample population, such as the tumor
type, cancer stages, duration from cancer onset, or physical complaint.
Second, we should consider what intervention method is appropriate as
a control group for AMT. In this study, we used a semi-structured chat,
which might include psychotherapeutic dimensions, which made com-
parison difﬁcult. A subsequent RCT might incorporate non-Anma relaxa-
tion practices like yoga or meditation for the control group. In addition,
we may review more suitable outcome measures, such as interleukin 6
or 10, which may be good candidates for outcomes for AMT. Moreover,
AMT is Japanese medical massage that is speciﬁcally tailored to a recipi-
ents' individual physical andmental state, and thismakes it difﬁcult to de-
velop a standard AMT pragmatic protocol because the degree of
stimulation must be adjusted to the individual. These limitations might
have led to the low levels of evidence in the present study. Nevertheless,
ourﬁndings can helpmedical professionals explain the beneﬁts of AMT to
gynecologic cancer survivors and provides higher quality information to
better inform patients in their decision whether to receive AMT or not.
5. Conclusion
A simple 40-min AMT session reduced the severity of subjective
physical complaints and the effect was sustained by continuous once
weekly AMT in gynecologic cancer survivors. These results imply that
AMT has beneﬁts in oncology.
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